 FREEHOLD, N.J., Oct. 07, 2021 GLOBE NEWSWIRE -- Avalon GloboCare Corp. NASDAQ: AVCO Avalon or The Company, a clinical-stage global developer of cell-based technologies and therapeutics, today announced co-development of a novel, cell-free, in-silico system to facilitate the Companys drug development efforts, together with the Institute for Synthetic Bioarchitectures at the University of Natural Resources and Life Sciences BOKU in Vienna, Austria. A study of the new technology was featured in the September 2021 issue of Membranes, an international, peer-reviewed journal. 